News

The study delves into the role of BEND4 in DNA damage repair and its potential as a therapeutic marker when combined with ATM inhibitor treatment.
A novel discovery in the field of pancreatic cancer treatment has been unveiled, revealing the epigenetic silencing of BEND4 as a potential synthetic lethal marker for enhancing the efficacy of ...
This suggests that the epigenetic silencing of BEND4 can serve as a biomarker for predicting the response to ATM inhibitors in pancreatic cancer treatment.
We designed a forward chemical genetic screen to identify inhibitors of the MRN-ATM pathway, and we isolated mirin as an inhibitor of MRN.
A pivotal finding of this research is the synthetic lethal effect when BEND4 expression is lost in combination with ATM inhibitor treatment. The study showed that PDAC cells with BEND4 methylation ...
SAN DIEGO – AZD1390, an ataxia telangiectasia mutant (ATM) kinase inhibitor, demonstrated a manageable safety profile in both recurrent and newly diagnosed glioblastoma (GBM) patients when ...
Of the identified kinase inhibitors, the researchers chose to test the effectiveness of the ataxia-telangiectasia mutated (ATM) inhibitor in the lab.
Researchers from Wayshine Biopharm Holding Ltd. published new data regarding the preclinical systemic pharmacokinetics (PK), dose proportionality, and central nervous system (CNS) distribution of the ...
The authors began by generating several DMG mouse models and identifying the conditions under which Atm loss or pharmacological inhibition with brain-penetrant ATM inhibitor AZD1390 leads tumors ...
A novel discovery in the field of pancreatic cancer treatment has been unveiled, revealing the epigenetic silencing of BEND4 as a potential synthetic lethal marker for enhancing the efficacy of ...